Literature DB >> 30451376

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

T J Girard1, N M Lasky1, K Grunz1, G J Broze1.   

Abstract

Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Suppression of the PZ/ZPI pathway may ameliorate the phenotype of severe hemophilia.
SUMMARY: Background Hemostasis requires a balance between procoagulant and anticoagulant factors. Hemophiliacs bleed because of a procoagulant deficiency. Targeted reduction in the activity of endogenous anticoagulant pathways is currently being investigated as a means of improving hemostasis in hemophilia. Protein Z (PZ) is a cofactor that serves as a catalyst for PZ-dependent protease inhibitor (ZPI) inactivation of activated factor X at phospholipid surfaces. Objectives To evaluate the effects of PZ or ZPI gene deletion in hemophilic mice, and of blocking PZ in human hemophilic plasma. Methods A tail vein rebleeding assay (TVRB) was developed on the basis of the serial disruption of clots forming over a period of 15 min following tail vein laceration in an anesthetized mouse. Wild-type (WT)/FVIII knockout FVIIIKO, PZ knockout PZKO/FVIIIKO and ZPI knockout ZPIKO/FVIIIKO mice were evaluated in this model, and their plasmas were tested in thrombin generation assays. A mAb against PZ was evaluated in human hemophilic plasma thrombin generation assays. Results The numbers of clot disruptions (mean ± standard error of the mean) in the TVRB were: 4.0 ± 0.9 for WT/FVIIIKO mice; 23.8 ± 1.1 for WT/FVIIIKO mice supplemented with 100% FVIII; 15.2 ± 1.1 for PZKO/FVIIIKO mice; and 14.7 ± 1.2 for ZPIKO/FVIIIKO mice. Thrombin generation in PZKO/FVIIIKO and ZPIKO/FVIIIKO mouse plasmas was similar to that in FVIIIKO plasma supplemented with ~ 15% recombinant FVIII. A mAb against PZ added to human hemophilic plasma enhanced thrombin generation to an extent similar to the addition of ~ 15% FVIII. Conclusions Blockade of the PZ/ZPI system may be sufficient to ameliorate the phenotype of severe hemophilia.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood coagulation; factor VIII; hemophilia A; hemostasis; mice

Mesh:

Substances:

Year:  2018        PMID: 30451376      PMCID: PMC6322933          DOI: 10.1111/jth.14337

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  44 in total

Review 1.  Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis.

Authors:  Javier Corral; Rocio González-Conejero; David Hernández-Espinosa; Vicente Vicente
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

Review 2.  Data management in thrombin generation.

Authors:  H Coenraad Hemker; R Kremers
Journal:  Thromb Res       Date:  2012-11-13       Impact factor: 3.944

3.  Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.

Authors:  Yesim Dargaud; Suzette Béguin; Anne Lienhart; Raed Al Dieri; Christine Trzeciak; Jean Claude Bordet; H Coenraad Hemker; Claude Negrier
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

4.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

5.  Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency.

Authors:  Jing Zhang; Yizheng Tu; Lan Lu; Nina Lasky; George J Broze
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

6.  Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa.

Authors:  Xin Huang; Richard Swanson; George J Broze; Steven T Olson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

7.  Isolation of a protein Z-dependent plasma protease inhibitor.

Authors:  X Han; R Fiehler; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.

Authors:  L R Jalbert; E D Rosen; L Moons; J C Chan; P Carmeliet; D Collen; F J Castellino
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.

Authors:  Yang Buyue; Herbert C Whinna; John P Sheehan
Journal:  Blood       Date:  2008-07-22       Impact factor: 22.113

10.  Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Authors:  P Chowdary; S Lethagen; U Friedrich; B Brand; C Hay; F Abdul Karim; R Klamroth; P Knoebl; M Laffan; J Mahlangu; W Miesbach; J Dalsgaard Nielsen; M Martín-Salces; P Angchaisuksiri
Journal:  J Thromb Haemost       Date:  2015-04-06       Impact factor: 5.824

View more
  4 in total

1.  Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.

Authors:  Xin Huang; Richard Swanson; Heather K Kroh; Paul E Bock
Journal:  J Biol Chem       Date:  2019-03-27       Impact factor: 5.157

2.  Engineering a protein Z-dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment.

Authors:  Xin Huang
Journal:  J Thromb Haemost       Date:  2019-09-05       Impact factor: 5.824

Review 3.  Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders.

Authors:  Elsa P Bianchini; Claire Auditeau; Mahita Razanakolona; Marc Vasse; Delphine Borgel
Journal:  Front Cardiovasc Med       Date:  2021-01-07

Review 4.  Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Authors:  Steven P Grover; Nigel Mackman
Journal:  Front Cardiovasc Med       Date:  2022-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.